Conditions: Solid Malignancies
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 35
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine the dose limiting toxicities, minimum tolerated dose and recommended dose for Phase II studies.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Ixabepilone
Intervention descriptions: intervention 1: Intravenous (IV) Infusion; 10, 20, 30, 35, 40 \& 45 mg/m2, once every 21 days (1 cycle), up to 9 cycles

Protocol document: